← All organizations
Highest phase reached
Phase 3
First clinical trial
Apr 1, 2003First marketed drug
Dec 14, 2012First NDA
Dec 14, 2012Last known activity
Dec 15, 2018
Acquired by Takeda on Feb 1, 2017
Timeline
1990s
- Jan 1, 1991
Ariad Pharmaceuticals— Founded
2010s
- Feb 1, 2017
Takeda— Acquired By
- Apr 28, 2017
brigatinib— NDA Organization
- Apr 28, 2017
brigatinib— NDA Secondary Org
Drugs by trial phase (25 distinct, 42 trials)
Phase 3 (7 own, 0 via acquisition)
Phase 2 (15 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Indications
Approved for
Studied for
- Adenocarcinoma
- Adenocarcinoma of Lung
- Blast Crisis
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Endometrial Neoplasms
- Gastrointestinal Stromal Tumors
- Glioblastoma
- Glioma
- Gliosarcoma
- Hepatic Insufficiency
- Leiomyosarcoma
- Leukemia
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Accelerated Phase
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid, Chronic-Phase
- Liposarcoma
- Liver Failure
- Lung Neoplasms
- Lymphoma
- Lymphoma, Large-Cell, Anaplastic
- Metaplasia
- Multiple Myeloma
- Myelodysplastic Syndromes
- Neoplasms
- Osteosarcoma
- Philadelphia Chromosome
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Primary Myelofibrosis
- Prostatic Neoplasms
- Sarcoma
- Small Cell Lung Carcinoma
- Syndrome
Marketed drugs (2)
Recent trials (50)
- NCT03596866Lead sponsorPhase 3Dec 15, 2018
- NCT03596866Study directorPhase 3Dec 15, 2018
- NCT03420742Study directorPhase 1Oct 29, 2018
- NCT03420742Lead sponsorPhase 1Oct 29, 2018
- NCT03535740Lead sponsorPhase 2Oct 21, 2018
- NCT03535740Study directorPhase 2Oct 21, 2018
- NCT03147612CollaboratorPhase 2Aug 1, 2017
- NCT02706626CollaboratorPhase 2Mar 9, 2017
- NCT02829840CollaboratorPhase 1/Phase 2Sep 1, 2016
- NCT02784158Lead sponsorN/AMay 24, 2016
- NCT02737501Lead sponsorPhase 3Apr 1, 2016
- NCT02716116Lead sponsorPhase 1/Phase 2Apr 1, 2016
- NCT02627677Lead sponsorPhase 3Dec 1, 2015
- NCT02467270Lead sponsorPhase 2Jun 1, 2015
- NCT01935336CollaboratorPhase 2May 21, 2014
Details
- Founded
- Cambridge, MA, US Jan 1, 1991
- First NDA
- Dec 14, 2012
- Last known activity
- Dec 15, 2018
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval
Notes
Acquired by Takeda in 16 Feb 2017